Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study

We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients.